Q. As a global bio-pharmaceutical consulting firm, thank you for sponsoring BIX again this year following last year. We appreciate your continued support and would like to know how your past participation has contributed to your business success. Additionally, what kind of business matching are you expecting this year, and which visitors are you looking forward to meeting at BIX 2024?

A. We are very pleased to attend BIX again this year witnessing BIX’s continuous growth each year. Last year, we had the opportunity to introduce IQVIA to many biopharmaceutical companies who were previously unaware of our various services and solutions. We also had the chance to network and explore business opportunities through partnering with several companies. This year, IQVIA plans to bring an expert from our headquarters with extensive knowledge in various types of deals and acquisitions happening in the global biopharmaceutical industry, as well as a specialist in the U.S. regulatory field. We aim to meet with numerous companies planning to enter overseas markets, particularly the U.S. market.

Q. Recently, you mentioned at IQVIA Insights Forum that it is important to gain insight into a wider range of stakeholders. At BIX, which encompasses the entire bio-pharmaceutical industry from R&D to logistics, have you been able to fulfill this aspect?

A. On May 8, IQVIA held an event titled "IQVIA Insight Forum 2024: Go Global with IQVIA." We gathered representatives from various companies planning to enter Global markets and shared insights on a wide range of areas that IQVIA can support, from R&D strategies to commercialization strategies. At BIX, where a broad spectrum of biopharmaceutical companies will be present, we look forward to showcasing IQVIA's capabilities from clinical development to commercialization and offering our support to more companies based on our capabilities.

Q. At BIX 2023, you provided insights for companies preparing to enter the U.S. market. For BIX 2024, could you introduce the topics IQVIA will cover and the audiences who will benefit from them?

A. Last year, through the corporate sessions hosted by IQVIA, we were able to meet many representatives from companies preparing to enter the U.S. market. This year, we aim to provide more detailed insights into the rapidly changing and complex U.S. regulatory trends with an IQVIA expert. We will also introduce various trends in new market entries, licensing out, and deals with Murray Aitken, the head of IQVIA's think tank, IQVIA Institute. Through this, we aim to introduce broader opportunities for entering global markets.

Q. BIX 2024 has expanded its exhibition scale compared to last year. From IQVIA’s perspective, which program are you most looking forward to at BIX 2024?

A. As the scale of BIX grows each year, we can also see that the various programs offered are increasingly filled with high-quality content. At BIX 2024, IQVIA Korea will focus on partnering and conferencing. We plan to introduce IQVIA Korea's services and offerings to more companies than last year through partnering and share ways we can directly assist them. Through technical session and sponsor session, we hope to share the insights that IQVIA has accumulated over many years with a broader audience.